Subscribe to stay informed!
After failing to convince the Food and Drug Administration that there is no need for additional testing for its lead new drug candidate, Malvern-based…
Malvern-based Galera Therapeutics is developing solutions that are reducing the negative side effects of radiation therapy and helping to improve treatment and outcomes for…
At $12 a share, Malvern-based Galera Therapeutics raised $60 million in its initial public offering and is now trading under the GRTX symbol on…
Before we send you to this site, please subscribe to our daily newsletter.